<DOC>
	<DOCNO>NCT03044379</DOCNO>
	<brief_summary>Dapivirine Gel Rectal Safety PK Study</brief_summary>
	<brief_title>Dapivirine Gel Rectal Safety PK Study</brief_title>
	<detailed_description>A Randomized , Double Blind , Placebo-Controlled Phase 1 Safety Pharmacokinetic Study Dapivirine Gel ( 0.05 % ) Administered Rectally HIV-1 Seronegative Adults</detailed_description>
	<criteria>Age 18 45 year ( inclusive ) , verify per site SOP Able willing provide write informed consent HIV1/2 uninfected Screening Enrollment , per applicable algorithm Appendix II willing receive HIV test result Able willing provide adequate locator information , define site SOP Available return study visit willing comply study participation requirement In general good health Screening Enrollment , determine site IoR designee Per participant report , history consensual RAI least past calendar year Willing take part research study involve drug , medical device , genital product , vaccine duration study participation , include time Screening Enrollment At Screening : Hemoglobin Grade 1 higher* Platelet count Grade 1 higher* White blood count Grade 2 higher* Serum creatinine 1.3 site laboratory upper limit normal ( ULN ) International normalize ratio ( INR ) 1.5 site laboratory ULN Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) Grade 1 higher* Positive hepatitis C antibody Positive hepatitis B surface antigen History inflammatory bowel disease participant report</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>